FACT SHEET v1.0 · May 2026
Cancer Series

Non-muscle-invasive bladder cancer: the essentials

Your bladder cancer has not reached the muscle layer of the bladder wall. This kind of cancer still comes back often, so you will get cystoscopies on a schedule for years. The goal is to keep your bladder and to catch any return early.

3 in 4
New bladder cancers are non-muscle-invasive at the time they are found.
Recurrence
About half to two-thirds have a new tumor within 5 years. Most are caught early on cystoscopy.
Progression
Less common. The cancer grows deeper or higher grade. Risk depends on your risk group.

What recurrence and progression mean

Recurrence means a new tumor of about the same kind. Progression means the cancer reaches a deeper layer or a higher grade. Most non-muscle-invasive cancers come back at some point, and far fewer ever progress. Your risk group tells you which is more likely for you.

Your risk group drives the plan

After your first surgery (TURBT, or transurethral resection of bladder tumor), your team sorts your case into one of three risk groups. They look at stage, grade, tumor size, number of tumors, and whether you have CIS (carcinoma in situ). Your group sets which bladder medicine you get and how often you are scoped.

Low
Ta, low-grade
Small, single, first-time tumor. About 3 to 4 in 10 come back within 5 years. Almost none grow deeper.
Intermediate
Larger, multiple, or back again
Low-grade Ta. About 5 to 7 in 10 come back within 5 years. Often needs a course of bladder medicine.
High
T1, high-grade, or CIS
Most come back. Needs BCG (bacillus Calmette-Guerin) or another bladder treatment. Closer follow-up, often for life.
The treatment path most people follow

TURBT

Surgery through the urethra to scrape out the tumor. Same-day or one-night stay. Gives the tissue diagnosis and is the first treatment.

One dose of bladder chemo

For low and many intermediate cases, one dose of mitomycin or gemcitabine goes into the bladder within 24 hours of TURBT. It lowers the chance of an early new tumor by about a third.

Re-TURBT for high-grade T1

A second TURBT 4 to 6 weeks later. About 1 in 3 to 1 in 2 high-grade T1 cases have leftover disease. About 1 in 10 are upstaged to muscle-invasive.

Bladder medicine course

BCG is the long-time first choice for high risk. Mitomycin, gemcitabine, or gemcitabine plus docetaxel are options, especially with BCG in short supply.

BCG: what to expect

Induction, then maintenance

Six weekly doses up front (induction), then three weekly doses at 3, 6, 12, 18, 24, 30, and 36 months. Up to three years total for high-risk cases.

Side effects are usually local

Burning, frequency, and urgency for 1 to 2 days after each dose. Low-grade fever and tiredness are common.

BCG is in short supply

Only one US maker. Your team may use a split dose (one vial across two or three patients) or a different bladder drug. Gemcitabine plus docetaxel has comparable response rates, and mitomycin has decades of data behind it.

Call the same day

Your temperature goes over 100.4 F. Shaking chills, joint pain, or a rash start up. You feel very unwell in the 24 to 48 hours after a dose. This is rare, and it is treated quickly.

Your cystoscopy schedule

How often you are scoped depends on your risk group. Low risk: 3 months, then 6 to 9 months, then yearly. Intermediate: every 3 to 6 months for 2 years, then every 6 to 12 months, then yearly out to about 10 years. High risk: every 3 months for 2 years, every 6 months through year 5, then yearly, often for life. A CT or MR urogram checks the kidneys and ureters every 1 to 2 years. Each scope takes 2 to 5 minutes and uses numbing jelly.

If BCG stops working: bladder-saving options

Since 2020, three FDA-approved treatments let many people keep their bladder when BCG fails. Pembrolizumab (IV every few weeks). Nadofaragene firadenovec (in the bladder every 3 months). Nogapendekin alfa with BCG (in the bladder). Removing the bladder is still on the table, especially if these stop working. Ask about all four options.

What you can do

Quit smoking, stay quit

The data on lowering recurrence by quitting is mixed. The heart, lung, and second-cancer benefits are clear. Medicine plus counseling roughly doubles the odds of still being smoke-free at one year.

Keep every cystoscopy

A missed scope gives a new tumor time to grow. Put the next year of appointments on your calendar.

Report new blood right away

You see pink or red urine between visits. Call, even if it stops by itself. Do not wait for the next scope.

Get a second opinion if it is high-risk

For CIS, high-grade T1, or BCG-unresponsive disease, ask about a second opinion. A center that treats a lot of bladder cancer is a good place to get one. New drugs keep coming.

Questions to bring to your next visit
  • What is my risk group (low, intermediate, or high), and what does that mean for me?
  • Did the TURBT include muscle in the sample, and do I need a re-TURBT?
  • Which bladder medicine are you recommending, and why?
  • Is BCG available for me? Or are we using another drug because of the shortage?
  • What is my cystoscopy schedule for the next 2 years?
  • If BCG does not work, what are my bladder-saving options before cystectomy?
  • Are there clinical trials open for me?

Go to the ER

You cannot urinate at all (acute retention). You see heavy blood with clots you cannot pass. Your temperature goes over 100.4 F with shaking chills, especially after a BCG dose. Severe belly or flank pain comes with a fever. You feel very unwell after a BCG dose, with a fast heart rate or low blood pressure.

Want the full picture?

The full Non-Muscle-Invasive Bladder Cancer Patient Guide goes deeper. It has the risk groups side by side and the full BCG schedule. It also covers the BCG shortage and its workarounds, the three new BCG-unresponsive options, the surveillance tables, and questions for your team.